Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Research

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India

Atul Patel1, Ritesh Agarwal12, Shivaprakash M. Rudramurthy, Manoj Shevkani, Immaculata Xess, Ratna Sharma, Jayanthi Savio, Nandini Sethuraman, Surabhi Madan, Prakash Shastri, Deepak Thangaraju, Rungmei Marak, Karuna Tadepalli, Pratik Savaj, Ayesha Sunavala, Neha Gupta, Tanu Singhal, Valliappan Muthu, Arunaloke Chakrabarti2Comments to Author , and MucoCovi Network3
Author affiliations: Sterling Hospital, Ahmedabad, India (A Patel); Postgraduate Institute of Medical Education & Research, Chandigarh, India (R. Agarwal, S.M. Rudramurthy, V. Muthu, A. Chakrabarti); Avaron Hospital, Ahmedabad (M. Shevkani); All India Institute of Medical Science, New Delhi, India (I. Xess); Apollo Hospital, Hyderabad, India (R. Sharma); St. John’s Medical College, Bengaluru, India (J. Savio); Apollo Hospital, Chennai, India (N. Sethuraman); Care Institute of Medical Sciences, Ahmedabad (S. Madan); Sir Ganga Ram Hospital, New Delhi (P. Shastri); Kovai Medical Centre and Hospital, Coimbatore, India (D. Thangaraju); Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India (R. Marak); All India Institute of Medical Sciences, Bhopal, India (K. Tadepalli); Venus Hospital, Surat, India (P. Savaj); Hinduja Hospital, Mumbai, Maharashtra, India (A. Sunavala); Medanta The Medicity, Gurgaon, India (N. Gupta); Kokilaben Hospital, Mumbai, Maharashtra, India (T. Singhal)

Main Article

Table 2

Multivariate analysis of factors predicting death at 6 weeks among patients with mucormycosis, India*

Variables Survivors, n = 177 Non-survivors, n = 110 Odds ratio (95% CI) p value
Mean age, y (SD)
 52.6 (15.1)
 54.7 (14.0)
 1.02 (1.00–1.04)
 0.03
Underlying disease
None 10 (5.6) 9 (8.2) Referent Referent
  Isolated COVID-19 42 (23.7) 19 (17.3) 0.56 (0.17–1.83) 0.34
  Diabetes mellitus 109 (61.6) 71 (64.5) 0.92 (0.32–2.64) 0.88
  Traumatic inoculation 8 (4.5) 4 (3.6) 1.30 (0.25–6.80) 0.76
  Others 5 (2.8) 3 (2.7) 1.20 (0.18–7.81) 0.85
  Renal transplantation 1 (0.6) 2 (1.8) 6.87 (0.42–113.19) 0.18
  Hematological malignancy
 2 (1.1)
 2 (1.8)
 1.60 (0.14–18.72)
 0.71
Site of involvement
  Rhino-orbital 117 (66.1) 50 (45.5) Referent Referent
  Rhino-orbito-cerebral 39 (22) 39 (35.5) 2.39 (1.30–4.40) 0.005
  Pulmonary 8 (4.5) 14 (12.7) 3.26 (1.05–10.11) 0.04
  Other†
 13 (7.3)
 7 (6.4)
 1.29 (0.43–3.86)
 0.64
Admission to the intensive care unit
 32 (18.1)
 35 (31.8)
 2.87 (1.43–5.75)
 0.003
Combined medical surgical therapy
 135 (76.3)
 69 (62.7)
 0.77 (0.41–1.45)
 0.41
Combination of antifungals
  Single antifungal drug 95 (53.7) 88 (80) Referent Referent
  Concurrent 9 (5.1) 5 (4.5) 0.37 (0.09–1.44) 0.15
  Sequential 73 (41.2) 17 (15.5) 0.17 (0.87–0.35) 0.0001

*Values are no. (%) except as indicated. Bold text indicates statistical significance. COVID-19, coronavirus disease. †Includes cutaneous, stomach, disseminated, or other.

Main Article

1These first authors contributed equally to this article.

2These senior authors contributed equally to this article.

3Members are listed at the end of this article.

Page created: June 02, 2021
Page updated: August 17, 2021
Page reviewed: August 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external